Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
8(67%)
Results Posted
300%(3 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
5
42%
Ph phase_2
6
50%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
6(54.5%)
N/ANon-phased studies
5(45.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

8

trials recruiting

Total Trials

12

all time

Status Distribution
Active(8)
Completed(1)
Terminated(3)

Detailed Status

Active, not recruiting6
Recruiting2
Withdrawn2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
8
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (54.5%)
N/A5 (45.5%)

Trials by Status

recruiting217%
completed18%
terminated18%
withdrawn217%
active_not_recruiting650%

Recent Activity

8 active trials
Showing 5 of 12
active_not_recruitingphase_2

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
active_not_recruitingphase_2

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062
active_not_recruitingnot_applicable

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

NCT00185744
recruitingnot_applicable

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

NCT03909282
recruitingnot_applicable

Cryoablation vs Lumpectomy in T1 Breast Cancers

NCT05505643
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04266249Phase 2

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Active Not Recruiting
NCT02883062Phase 2

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Active Not Recruiting
NCT00185744Not Applicable

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

Active Not Recruiting
NCT03909282Not Applicable

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

Recruiting
NCT05505643Not Applicable

Cryoablation vs Lumpectomy in T1 Breast Cancers

Recruiting
NCT02927912Phase 2

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Active Not Recruiting
NCT04595435

IORT-Breast at Medical Center Navicent Health

Active Not Recruiting
NCT05545150Phase 2

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

Active Not Recruiting
NCT00290654Phase 2

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

Terminated
NCT00373152Phase 2

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

Withdrawn
NCT02432118Not Applicable

Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy

Withdrawn
NCT00749931Not Applicable

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

Completed

All 12 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
12